Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Filgotinib is an oral small molecule that selectively inhibits JAK1. It is already approved for the treatment of moderately to severely active ulcerative colitis (UC). Ongoing studies are evaluating the efficacy and safety of filgotinib in Crohn's disease (CD). The purpose of this review is to summarize the available data regarding filgotinib in the management of UC and CD. We used Pubmed, Embase and clinicaltrials.gov websites to search all available data and currently ongoing studies regarding the efficacy and safety of filgotinib in inflammatory bowel diseases. Filgotinib is an effective and safe drug for the management of biologic-naive and biologic-experienced patients with moderate-to-severe UC. The same efficacy results have not been achieved in CD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/imt-2023-0116 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pleurotus citrinopileatus polysaccharides ameliorate DSS-induced ulcerative colitis by improving intestinal barrier and inflammation modulation via NF-κB pathway.
Int J Biol Macromol
September 2025
Laboratory of Tumor Immunology, The first Hospital of Jilin University, Changchun, 130021, China. Electronic address:
The aim was to investigate the pharmacological effects of a polysaccharide isolated from Pleurotus citrinopileatus on ulcerative colitis (UC). One polysaccharide, CP-2-2, was isolated and purified from P. citrinopileatus body fruit using chromatographic methods.
View Article and Find Full Text PDFThe role of CT Colonography in the assessment of inflammatory bowel Diseases patients.
Eur J Radiol
August 2025
Unità Operativa di Radiologia, ASST Fatebenefratelli Sacco, L. Sacco University Hospital, Milan, Italy. Electronic address:
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and Ulcerative Colitis (UC), is characterized by chronic inflammation of the gastrointestinal tract, and its long-standing course significantly elevates the risk of colorectal cancer (CRC), primarily arising from dysplastic lesions. While regular surveillance by colonoscopy is well established for UC patients, guidelines for CD remain uncertain. Computed Tomographic Colonography (CTC) offers a minimally invasive alternative for evaluating the colon, particularly in cases where colonoscopy is incomplete or contraindicated.
View Article and Find Full Text PDFPremna microphylla Turcz pectin-modified diosmetin nanoparticles: A galectin-3 targeting strategy for precise colitis intervention.
Carbohydr Polym
November 2025
Shenzhen Key Laboratory of Food Nutrition and Health, College of Chemistry and Environmental Engineering, Shenzhen University, Shenzhen 518060, PR China. Electronic address:
Oral delivery of natural antioxidants represents a promising therapeutic strategy for ulcerative colitis (UC), yet their therapeutic efficacy is hindered by instability and poor accumulation at inflamed sites. To address this, we developed Galectin-3 (Gal-3)-targeted nanoparticles (ZDP-NPs) by encapsulating diosmetin within zein complexes modified with a galactose- and rhamnogalacturonan-I (RG-I)-rich pectin (PMTP, Mw: 228.8 kDa, DM: 34.
View Article and Find Full Text PDFClinical Research: Disparities in Outcomes for Patients With Inflammatory Bowel Disease at a Private vs Public Hospital in New York City.
Inflamm Bowel Dis
September 2025
Division of Gastroenterology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, United States.
Background: In patients with inflammatory bowel disease (IBD), social determinants of health contribute to health inequalities. We aimed to compare patients with IBD treated at a private nonprofit vs public hospital in New York City.
Methods: We performed a retrospective study of adult patients with Crohn's disease or ulcerative colitis with established IBD care.
Usnoflast: A Cutting-Edge NLRP3 Inhibitor Attenuates Colonic Inflammation Across Diverse Immunopathology.
Eur J Pharmacol
September 2025
Zydus Research Centre, Zydus Lifesciences Limited, Sharkhej-Bavla NH No. 8A, Village Moraiya, Changodar, Ahmedabad-382 213, Gujarat, India.
NLR (Nod-like receptor) family pyrin domain containing protein 3 (NLRP3) inflammasome activation is key component of innate immune response and is implicated in many autoimmune conditions. Usnoflast is a novel, selective NLRP3-inflammasome inhibitor and is currently in Phase II for various indications including Ulcerative colitis. Here, we report the effect of usnoflast in several experimental models of intestinal inflammation, some of them for the first time for any NLRP3 inhibitor, which involves both innate and adaptive immune mechanisms.
View Article and Find Full Text PDF